17例SMARCA4缺失型胸部肿瘤临床特征与预后分析
回顾性分析济宁医学院附属医院2021年9月至2023年1月病理确诊的17例SMARCA4缺失型胸部肿瘤患者,分析其临床特征、影像、治疗及预后。患者以重度吸烟中老年男性为主,影像多为肺内或纵隔团块,易早期远处转移;含铂化疗联合免疫检查点抑制剂可能有效,早期手术可能改善预后。
要点
- 重度吸烟中老年男性出现肺内或纵隔团块、进展快、早转移需警惕SMARCA4缺失型胸部肿瘤。
- 含铂双药化疗联合免疫检查点抑制剂可能有效,早期手术可能改善预后。
- 临床分期晚是总体生存不良的高危因素。
核心结论
- 临床分期晚是SMARCA4缺失型胸部肿瘤患者总体生存不良的高危因素。
- 含铂双药化疗联合免疫检查点抑制剂治疗可能有效,早期手术可改善患者预后。
研究设计与样本
- 回顾性分析济宁医学院附属医院2021年9月至2023年1月病理确诊的17例SMARCA4缺失型胸部肿瘤患者。
- 收集患者一般情况、临床症状、肿瘤标志物、影像学特征、治疗及转归,并进行文献复习。
主要发现
- 17例患者中男16例、女1例,年龄42~74岁,平均(64.0±5.7)岁。
- 仅1例女性无明确吸烟史,16例男性均有吸烟史,其中1例5包年,余15例20~100包年,平均(68.5±44.5)包年。
- 临床症状以咳嗽、咳痰为主,其次为胸闷、咯血、胸痛。
- 影像示肺内或纵隔团块影,累及纵隔9例、右肺上叶6例、左肺上叶5例、右肺下叶3例、左肺下叶3例。
- 9例接受含铂双药化疗(其中4例联合免疫检查点抑制剂)及1例恩沙替尼治疗者中仅1例部分缓解,余8例进展;5例放弃治疗随访6个月均死亡;3例手术切除随访6个月无明显进展。
关键数值与推荐
- 肿瘤标志物CYFRA19-9升高9例(3.79~16.61 ng/ml)。
- CEA升高8例(5.37~295.93 ng/ml)。
- NSE升高6例(17.18~70.37 ng/ml)。
- 转移部位:颈部或锁骨上淋巴结8例,胸膜4例,肝3例,脑3例,骨2例,皮下1例。
- 病理结合免疫组化诊断SMARCA4缺失型非小细胞癌6例、SMARCA4缺失型未分化肿瘤11例。
临床怎么用
- 对重度吸烟中老年男性,影像见肺内和(或)纵隔团块、病灶进展快、远处转移早者,应警惕SMARCA4缺失型胸部肿瘤。
- 临床分期晚提示总体生存不良高风险,含铂双药化疗联合免疫检查点抑制剂可能有效。
- 早期手术可能改善患者预后。
局限性
- 本研究为单中心回顾性分析,样本量17例。
- 随访时间为6个月,观察期较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the clinical characteristics and prognosis of 17 patients with pathologically confirmed SMARCA4-deficient chest tumors. Methods: Seventeen patients with SMARCA4-deficient thoracic tumors diagnosed by pathology in the Affiliated Hospital of Jining Medical University from September 2021 to January 2023 were collected through Results Query System of Pathology Department, and the patients' general conditions, clinical symptoms, tumor markers, imaging features, treatment and regression were retrospectively analyzed, and literature review was performed. Results: A total of 17 patients were included in this study. Their clinical characteristics were characterized as follows: male/female=16/1, age 42-74 years, mean (64.0±5.7)years. Only 1 female had no clear smoking history, and 16 males had a smoking history, of whom 1 had 5 smoking pack-years, and the remaining 15 case had a smoking history of 20-100 smoking pack-years, with a mean of (68.5±44.5) smoking pack-years. Clinical symptoms were mainly cough and sputum, followed by chest tightness, hemoptysis and chest pain. Tumor markers CYFRA19-9 was elevated in 9 cases (3.79-16.61 ng/ml), CEA was elevated in 8 cases (5.37-295.93 ng/ml), and NSE was elevated in 6 cases (17.18-70.37 ng/ml). Imaging manifestations were intrapulmonary or mediastinal mass shadows, and the tumor involved the mediastinum in 9 cases, the upper lobe of the right lung in 6 cases, the upper lobe of the left lung in 5 cases, the lower lobe of the right lung in 3 cases, the lower lobe of the left lung in 3 cases; cervical or supraclavicular lymph node metastasis in 8 cases, pleural metastasis in 4 cases, hepatic metastasis in 3 cases, cerebral metastasis in 3 cases, bone metastasis in 2 cases, and subcutaneous metastasis in 1 case. Combining immuno-histochemistry and pathology, there were 6 cases of SMARCA4-deficient NSCLC and 11 cases of SMARCA4-deficient undifferentiated tumor. Eight patients were treated with platinum-contained chemotherapy agents, four of which were combined with immune checkpoint inhibitors, and one was treated with enzatinib; only one of the 9 patients achieved partial remission after treatment, and the remaining eight had progression of the tumors on chest CT after treatment. Five patients abandoned the treatment, and died in 6-month of follow-up. Three patients underwent surgery for resection, and there was no significant progression in the three patients in the 6 months of follow-up. Conclusions: Clinically, middle-aged and elderly men with a history of heavy smoking should be given high priority, especially in patients whose imaging mostly showed intrapulmonary, especially in upper lobes, and/or mediastinal masses, rapid lesion progression, and early distant metastasis, and who should be alerted to the possibility of SMARCA4-deficient thoracic tumors. Late clinical stage is a high risk factor for poor overall patient survival, and platinum-containing chemotherapy agents combined with immune checkpoint inhibitor therapy may be effective, and early surgery may improve patient prognosis. 目的: 分析病理确诊的17例SMARCA4缺失型胸部肿瘤患者的临床特征及预后分析。 方法: 通过病理科结果查询系统收集济宁医学院附属医院2021年9月至2023年1月病理确诊的17例胸部SMARCA4缺失型胸部肿瘤患者,其中男16例,女1例,年龄42~74(64.0±5.7)岁。对患者一般情况、临床症状、肿瘤标志物、影像学特征、治疗及转归等进行回顾性分析。 结果: 纳入的17例患者中,仅1例女性无明确吸烟史,16例男性均有吸烟史,其中1例吸烟量5包年,余15例吸烟量均在20~100包年,平均(68.5±44.5)包年。临床症状主要表现为咳嗽、咳痰,其次为胸闷、咯血、胸痛。肿瘤标志物CYFRA19-9升高9例(3.79~16.61 ng/ml)、CEA升高8例(5.37~295.93 ng/ml)、NSE升高6例(17.18~70.37 ng/ml)。影像学表现为肺内或纵隔团块影,肿瘤累及纵隔9例,右肺上叶6例、左肺上叶5例、右肺下叶3例、左肺下叶3例;颈部或锁骨上淋巴结转移8例,胸膜转移4例,肝转移3例,脑转移3例,骨转移2例,皮下转移1例。病理结合免疫组化诊断SMARCA4缺失型非小细胞癌6例及SMARCA4缺失型未分化肿瘤11例。8例患者应用含铂双药化疗,其中4例联合免疫检查点抑制剂治疗;1例服用恩沙替尼治疗。上述9例患者中仅1例患者治疗后达部分缓解,余8例治疗后复查胸部CT提示肿瘤均较前进展。5例患者放弃治疗,随访6个月均死亡。3例患者行外科手术切除治疗,随访6个月均无明显进展。 结论: 对于大量吸烟的中老年男性,尤其影像学表现为肺内和(或)纵隔内团块影,病灶进展快、远处转移早的患者,需警惕SMARCA4缺失型胸部肿瘤。临床分期晚是患者总体生存不良的高危因素,含铂双药化疗联合免疫检查点抑制剂治疗可能有效,早期手术可改善患者预后。.
引用
- Cao XN, Li Z, Wang QY, et al. [Clinical characteristics and prognosis analysis of 17 cases of SMARCA4-deficient chest tumors]. Zhonghua Jie He He Hu Xi Za Zhi. 2024. PMID: 38599807. doi:10.3760/cma.j.cn112147-20230927-00202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。